Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
17 hedge funds and large institutions have $4.51M invested in Reviva Pharmaceuticals Warrants in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
47% more capital invested
Capital invested by funds: $3.06M → $4.51M (+$1.45M)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$104K |
| 2 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$93.7K |
| 3 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$29.3K |
| 4 |
Walleye Capital
New York
|
+$14.9K |
| 5 |
HF
HRT Financial
New York
|
+$11.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$64K |
| 2 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$15.1K |
| 3 |
Walleye Trading
New York
|
-$13.7K |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$8K |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$5.86K |
RVPHW Hedge Fund Activity: Q2 2020 in Review
17 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q2 2020, worth a combined $4.51M — up 47% from $3.06M a quarter earlier.
Fund positioning in RVPHW was balanced in Q2 2020: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Glazer Capital LLC, adding an estimated $104K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $64K sold.
- 17 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $4.51M of Reviva Pharmaceuticals Warrants stock for Q2 2020, up 47% quarter-over-quarter.
- 4 funds opened new Reviva Pharmaceuticals Warrants positions in Q2 2020 and 4 closed out, a net change of 0 holders.
- The largest Reviva Pharmaceuticals Warrants buyer in Q2 2020 was Glazer Capital LLC, an estimated $104K added.
- The largest Reviva Pharmaceuticals Warrants seller in Q2 2020 was Hudson Bay Capital Management, an estimated $64K sold.
Based on aggregated 13F filings for Q2 2020.